Literature DB >> 26759082

Mycobacterium tuberculosis-Secreted Tyrosine Phosphatases as Targets Against Tuberculosis: Exploring Natural Sources in Searching for New Drugs.

Alessandra Mascarello, Louise Domeneghini Chiaradia-Delatorre, Mattia Mori1, Hernán Terenzi, Bruno Botta.   

Abstract

Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis (Mtb), which primarily affects the respiratory tract. Combinations of drugs are used for therapeutic synergism and to prevent the emergence of drug resistant strains, but even first- or secondchoice drugs present some disadvantages, such as significant side effects and the need for long duration of treatments. Thus, new strategies for TB control and treatment are highly demanded. In this context, protein tyrosine phosphatases (PtpA and PtpB) are secreted by Mtb within the host macrophage and they have been shown to contribute to Mtb pathogenicity. The understanding of the role of these PTPs has led to interesting anti-TB drugs discovery. Here, we review the current knowledge on these two proteins as targets for novel anti-TB therapies, with particular emphasis on their mechanism of action and current advancements in developing small molecule inhibitors from natural sources.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26759082     DOI: 10.2174/1381612822666160112130539

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  3 in total

1.  Dual-targeting GroEL/ES chaperonin and protein tyrosine phosphatase B (PtpB) inhibitors: A polypharmacology strategy for treating Mycobacterium tuberculosis infections.

Authors:  Alex Washburn; Sanofar Abdeen; Yulia Ovechkina; Anne-Marie Ray; Mckayla Stevens; Siddhi Chitre; Jared Sivinski; Yangshin Park; James Johnson; Quyen Q Hoang; Eli Chapman; Tanya Parish; Steven M Johnson
Journal:  Bioorg Med Chem Lett       Date:  2019-04-24       Impact factor: 2.823

2.  Synthesis, biological evaluation and molecular modeling studies on novel quinonoid inhibitors of CDC25 phosphatases.

Authors:  Emilie Evain-Bana; Lucie Schiavo; Christophe Bour; Don Antoine Lanfranchi; Simone Berardozzi; Francesca Ghirga; Denyse Bagrel; Bruno Botta; Gilles Hanquet; Mattia Mori
Journal:  J Enzyme Inhib Med Chem       Date:  2016-10-23       Impact factor: 5.051

3.  A significant therapeutic effect of silymarin administered alone, or in combination with chemotherapy, in experimental pulmonary tuberculosis caused by drug-sensitive or drug-resistant strains: In vitro and in vivo studies.

Authors:  Edén M Rodríguez-Flores; Dulce Mata-Espinosa; Jorge Barrios-Payan; Brenda Marquina-Castillo; Mauricio Castañón-Arreola; Rogelio Hernández-Pando
Journal:  PLoS One       Date:  2019-05-30       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.